摘要
目的探讨子宫肌瘤患者宫腔镜术后血清中IL-6、sCD40L水平与治疗效果及患者预后的关系。方法选取2015年11月-2016年11月本院妇科行腹腔镜手术治疗的子宫肌瘤患者90例,所有患者均采用酶联免疫吸附法检测血清中IL-6、sCD40L,探讨血清中IL-6、sCD40L水平与患者治疗效果的关系,采用Logistic回归分析探讨血清中IL-6、sCD40L与子宫肌瘤复发的关系。结果 sCD40L低水平、IL-6低水平的患者E2和P的水平均明显低于对应高水平的患者(P<0.05);sCD40L低水平、IL-6低水平的患者手术时间、术中出现、术后住院时间、术后并发症的发生均明显低于对应高水平的患者,差异有统计学意义(P<0.05);Logistic回归分析结果证实,sCD40L、IL-6是患者子宫肌瘤复发的独立危险因素(P<0.05)。结论血清中IL-6、sCD40L与患者治疗效果及预后密切相关,是子宫肌瘤复发的独立危险因素。
Objective To investigate the relationship of serum IL-6 and sCD40 L levels with therapeutic effect and prognosis in hysteromyoma patients after hysteroscopy. Methods A total of 90 patients with uterine myoma treated by laparoscopy in our hospital during November 2015-November 2016 were selected. IL-6 and sCD40 L in serum were detected by enzyme linked immunosorbent assay. The relationship of IL-6 and sCD40 L levels in serum with the therapeutic effect of patients was discussed. IL-6 and sCD4 in serum were analyzed by Logistics regression analysis, and the relationship with the recurrence of uterine myoma was discussed. Results The levels of E2 and P in patients with low levels of sCD40 L and IL-6 were significantly lower than those in patients with high levels(P<0.05). The operation time, intraoperative appearance, postoperative hospital stay, operation time and postoperative complications of patients with low levels of sCD40 L and IL-6 were significantly lower than those in high level patients, with the differences statistically significant(P<0.05). Logistic regression analysis confirmed that sCD40 L and IL-6 were independent risk factors for recurrence of uterine fibroids(P<0.05). Conclusion IL-6 and sCD40 L are closely related to the therapeutic effect and prognosis of hysteromyoma, and they are independent risk factors for the recurrence of uterine fibroids.
引文
[1] 周小飞,刘玉珠.腹腔镜下子宫肌瘤剔除术治疗子宫肌瘤以及对患者IL-6、IL-2和CRP的影响[J].中国内镜杂志,2017,23(11):19-23.
[2] 张晓英,姜晓春,张新选.腹腔镜以及开腹子宫肌瘤切除术后CRP、TNF-α、IL-6水平变化分析[J].标记免疫分析与临床,2015,22(9):909-911.
[3] 赵发兵,姚卫.血清sCD40L、sCD40含量与ACS患者病情进展、斑块性质改变的关系[J].海南医学院学报,2017,23(3):310-312,315.
[4] 许燕萍,宋曼莉,李巧能,等.80例多发子宫肌瘤腹腔镜手术的临床分析[J].中国处方药,2016,12(1):8-9.
[5] 田艺,张坤,苏青,等.腹腔镜下子宫肌瘤微创剔除术治疗子宫肌瘤临床疗效及对患者应激反应的影响研究[J].陕西医学杂志,2018,47(1):93-95.
[6] 赵冬梅.全面护理对子宫肌瘤微创手术患者的临床效果观察[J].中国现代药物应用,2017,11(17):163-164.
[7] 薛文丹,邢孔丽,李小清.腹腔镜超声辅助在子宫肌瘤患者微创手术中的应用研究[J].中国内镜杂志,2017,23(11):46-50.
[8] 薛峰,颜源,何攀.血浆sCD40L、sICAM-1及血管内皮损伤相关细胞与子痫前期严重程度的相关性分析[J].中国实验诊断学,2017,21(3):464-467.
[9] 刘娟,王欣.腹腔镜与开腹手术对子宫肌瘤患者炎症因子及免疫功能的影响[J].现代医药卫生,2017,33(11):1650-1652.
[10] 李彩荣,冯定庆,周颖,等.白细胞介素-6及其受体在子宫肌瘤的表达及意义[J].中国综合临床,2009,25(4):360-362.
[11] 辛华,周伟,邓伟雄,等.米非司酮对子宫肌瘤患者血清IL-6和TNF-α的影响[J].中国医药导报,2010,7(11):57-58.
[12] 高巍,张莉,翟丽丽,等.IL-6、TNF-α、VEGF、MCP-1因子在子宫内膜异位症患者血清中的表达及临床意义[J].宁夏医科大学学报,2016,38(6):696-698.
[13] 屠伟文.腹腔镜下子宫切除联合子宫动脉阻断治疗子宫肌瘤的应用价值[J].蚌埠医学院学报,2015,40(12):1678-1680,1683.
[14] 王一斌,黄洁贞,林耀华,等.细胞因子 TNF-a、IL-6在输卵管性不孕患者中的表达[J].广州医科大学学报,2015,8(3):76-78.
[15] 卢斋,陈华,钟业超,等.子宫肌瘤组织信号通路分子及MMPs、IL-6、IL-10的表达及临床意义[J].海南医学,2017,28(17):2762-2764.